Table 3. Prescriptions during the last 15 months for primary and secondary prevention in patients with type 2 diabetes, CHD, and stroke.

Treatment		Primary prevention			Secondary prevention
Treatment		No CVD, % n = 7511	Females, % n = 3687	Males, % n = 3824	CHD, % n = 2260	Stroke, % n = 759
Attained SBP targets		65.7	64.1	67.0^a	65.1	66.7
Blood pressure medication
	Thiazides	26.4	28.2	23.9	25.8	26.7
	ACE inhibitors or aII-receptor blockers	47.7	48.7	46.8	61.5^b	58.0^b
	Calcium channel blockers (dihydropyridines)	23.1	22.3	23.8	29.1^b	34.1^b
	Beta-blockers	16.9	19.0	14.9^b	65.6^b	46.1^b
	Other BP medication	1.6	1.2	2.0^a	2.9^b	2.2
	Mean number of BP medications (SD)	1.2 (1.3)	1.3	1.2	2.1 (1.4)^d	1.9 (1.4)^d
	No BP medication	42.8	39.5	46.0^b	15.8^b	21.6^b
	Patients with SBP above target, and not prescribed medication	26.9	-	-	14.3	17.3
Attainment of LDL target		-	-	-	30	-
Lipid-lowering medication
	Statin	45.5	45.6	45.4	76.7^b	66.8^b
	Ezetimibe	1.6	1.9	1.3^a	4.7^b	2.6
	No lipid-lowering medication	53.9	53.7	54.0	22.7^b	32.7^b
Anti-platelet therapy		22.8	21.6	24.1^a	74.6^b	66.3^b

Significance test performed with Poisson regression analysis comparing medication for males versus females, CHD versus non-CHD patients, and stroke versus non-stroke patients, respectively.
^aP<0.05. ^bP<0.001. Significance test performed with χ² test comparing males versus females, CHD versus non-CHD, stroke versus non-stroke, respectively.^cP<0.05.^dP<0.001.
ACE = angiotensin-converting enzyme. BP = blood pressure. CHD = coronary heart disease. CVD = cardiovascular disease. LDL = low-density lipoprotein. SBP = systolic blood pressure. SD = standard deviation.